Background: Liposomal formulation of anthracyclines provide better systemic and organ-specific tolerance, with potential for less local tissue damage during extravasation. Several small series have reported that most liposomal anthracycline extravasations are consistent with irritant injury without tissue necrosis. There have been no reports published regarding the clinical effects of extravasation of liposomal cytarabine-daunorubicin (CPX-351).
Case report: The patient received CPX-351 for relapsed acute myelogenous leukemia via a left chest wall port-a-catheter. The catheter became dislodged. Once symptoms developed, the infusion was discontinued, with observations demonstrating an 8-cm region of edema, warmth, no erythema, and no drainage. Limited supportive management was performed. Physical examination the following day demonstrated no evidence of necrosis, and erythema resolved completely without additional intervention.
Conclusion: CPX-351 extravasation behaving as an irritant is consistent with the reports of other liposomal anthracyclines.
Keywords: CPX-351; anthracycline extravasation; extravasation; irritant; liposomal daunorubicin; vesicant.
Copyright© 2018, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.